zapnometinib

SKU: orb1298188

Description

Zapnometinib (ATR-002) is a selective small molecule inhibitor targeting the MEK kinase. It is utilized in biochemical and cellular research to investigate MAPK/ERK pathway signaling and has been studied in preclinical models for its potential therapeutic effects.

Research Area

Infectious Disease & Virology, Signal Transduction

Key Properties

• CAS Number: 303175-44-2
• MW: 409.55
• Purity: 99.67%
• Formula: C₁₃H₇ClF₂INO₂
• SMILES: OC(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl
• Target: MEK,Influenza Virus,Antibacterial
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.88 mM);DMSO:60 mg/mL (146.5 mM)

Bioactivity

• Target IC50:
  MEK:5.7 nM
• In Vivo:
  Zapnometinib exhibits AUC values of 860.02 and 1953.68 μg h/mL in mice by i.v. or oral route, respectively.Zapnometinib reduces the lung virus titers and enhances survival of mice after lethal H1N1pdm09 infection.
• In Vitro:
  Zapnometinib inhibits MEK, with IC50s of 30.96 nM, 357 nM, and 15 nM in cell free kinase assay, A549, MDCK cells and human PBMCs.Zapnometinib reduces the viral titers of the IV H1N1pdm09, H3N2.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CI-1040, antiviral, antibacterial, ATR 002, ATR002, ATR-002, Bacterial, 3,4-difluoro-2-(2-chloro-4-iodophenylaMino)-benzoic acid, 2-(2-chloro-4-iodoanilino)-3,4-difluorobenzoic acid, MEK, MAPKK, MAP2K, Inhibitor, inhibit, influenza, Influenza Virus, InfluenzaVirus, PD 0184264, PD0184264, PD-0184264, Mitogen-activated protein kinase kinase, zapnometinib, virus

Compound Identifiers

PubChem CID

10112191